42 related articles for article (PubMed ID: 26718028)
1. Computational insights into overcoming resistance mechanisms in targeted therapies for advanced breast cancer: focus on EGFR and HER2 co-inhibition.
Abdulaziz O; Khan FR; Alharthi NS; Alhuthali HM; Hazazi A; Alzahrani HA; Gharib AF; Alsalmi OA; Hawsawi NM; Alhazmi AY
J Biomol Struct Dyn; 2024 Jan; ():1-12. PubMed ID: 38234016
[TBL] [Abstract][Full Text] [Related]
2.
Situmorang PC; Ilyas S; Syahputra RA; Sari RM; Nugraha AP; Ibrahim A
Front Pharmacol; 2024; 15():1345645. PubMed ID: 38476328
[TBL] [Abstract][Full Text] [Related]
3. Long Noncoding RNAs in Taxane Resistance of Breast Cancer.
Chen H; Zhang M; Deng Y
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569629
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system.
Sun X; Zhao P; Lin J; Chen K; Shen J
Cancer Drug Resist; 2023; 6(2):390-415. PubMed ID: 37457134
[TBL] [Abstract][Full Text] [Related]
5. Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma.
Devan AR; Kumar AR; Nair B; Anto NP; Muraleedharan A; Mathew B; Kim H; Nath LR
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358082
[TBL] [Abstract][Full Text] [Related]
6. Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype.
Al-Zeheimi N; Adham SA
Br J Pharmacol; 2020 May; 177(9):2024-2041. PubMed ID: 31883395
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.
Li W; Wang Y; Tan S; Rao Q; Zhu T; Huang G; Li Z; Liu G
Med Sci Monit; 2018 Oct; 24():7178-7185. PubMed ID: 30296252
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells.
Majumder A; Ray S; Banerji A
Mol Cell Biochem; 2019 Feb; 452(1-2):111-121. PubMed ID: 30074136
[TBL] [Abstract][Full Text] [Related]
9. EGFR and Cortactin: Markers for potential double target therapy in oral squamous cell carcinoma.
Bissinger O; Kolk A; Drecoll E; Straub M; Lutz C; Wolff KD; Götz C
Exp Ther Med; 2017 Nov; 14(5):4620-4626. PubMed ID: 29201160
[TBL] [Abstract][Full Text] [Related]
10. Blood cadmium levels associated with short distant metastasis-free survival time in invasive breast cancer.
He Y; Peng L; Huang Y; Liu C; Zheng S; Wu K
Environ Sci Pollut Res Int; 2017 Dec; 24(36):28055-28064. PubMed ID: 28994009
[TBL] [Abstract][Full Text] [Related]
11. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells.
Xu JW; Li QQ; Tao LL; Cheng YY; Yu J; Chen Q; Liu XP; Xu ZD
Int J Oncol; 2011 Dec; 39(6):1501-9. PubMed ID: 21805028
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine.
Germano S; O'Driscoll L
Curr Cancer Drug Targets; 2009 May; 9(3):398-418. PubMed ID: 19442059
[TBL] [Abstract][Full Text] [Related]
13. Targeting HER2 heterogeneity in breast cancer.
Hamilton E; Shastry M; Shiller SM; Ren R
Cancer Treat Rev; 2021 Nov; 100():102286. PubMed ID: 34534820
[TBL] [Abstract][Full Text] [Related]
14. EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.
Jin Y; Zhang W; Wang H; Zhang Z; Chu C; Liu X; Zou Q
Oncol Rep; 2016 Feb; 35(2):771-8. PubMed ID: 26718028
[TBL] [Abstract][Full Text] [Related]
15. UCH-L1 involved in regulating the degradation of EGFR and promoting malignant properties in drug-resistant breast cancer.
Jin Y; Zhang W; Xu J; Wang H; Zhang Z; Chu C; Liu X; Zou Q
Int J Clin Exp Pathol; 2015; 8(10):12500-8. PubMed ID: 26722437
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells.
Li QQ; Wang WJ; Xu JD; Cao XX; Chen Q; Yang JM; Xu ZD
Cancer Sci; 2007 Nov; 98(11):1767-74. PubMed ID: 17725804
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
